Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of
CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).